Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 241.59%: Read This Before Placing a Bet

Day One Biopharmaceuticals, Inc. (DAWN) closed the last trading session at $7.19, gaining 0.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $24.56 indicates a 241.6% upside potential.The average comprises nine short-term price targets ranging from a low of $16.00 to a high of $34.00, with a standard deviation of $5.36. While the lowest estimate indicates an increase of 122.5% fr ...